Swiss National Bank lessened its position in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 4.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 521,880 shares of the medical research company's stock after selling 25,800 shares during the period. Swiss National Bank owned about 0.28% of Exact Sciences worth $29,324,000 as of its most recent filing with the SEC.
Other large investors have also made changes to their positions in the company. Geode Capital Management LLC boosted its holdings in shares of Exact Sciences by 0.3% in the 3rd quarter. Geode Capital Management LLC now owns 3,105,970 shares of the medical research company's stock worth $211,104,000 after acquiring an additional 7,873 shares in the last quarter. Champlain Investment Partners LLC boosted its stake in Exact Sciences by 10.9% during the 3rd quarter. Champlain Investment Partners LLC now owns 2,494,480 shares of the medical research company's stock worth $169,924,000 after acquiring an additional 245,980 shares during the last quarter. Bellevue Group AG increased its stake in Exact Sciences by 25.1% in the third quarter. Bellevue Group AG now owns 1,449,465 shares of the medical research company's stock valued at $98,738,000 after purchasing an additional 290,585 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Exact Sciences by 3.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,330,939 shares of the medical research company's stock valued at $74,785,000 after buying an additional 38,849 shares during the period. Finally, Groupama Asset Managment bought a new stake in shares of Exact Sciences in the 3rd quarter valued at $821,000. Institutional investors own 88.82% of the company's stock.
Exact Sciences Stock Performance
Shares of EXAS traded up $1.34 during trading hours on Friday, hitting $45.62. The company's stock had a trading volume of 3,145,252 shares, compared to its average volume of 2,620,745. Exact Sciences Co. has a 52-week low of $40.62 and a 52-week high of $79.62. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93. The company has a market cap of $8.47 billion, a price-to-earnings ratio of -8.19 and a beta of 1.25. The business has a 50 day simple moving average of $50.77 and a two-hundred day simple moving average of $58.39.
Exact Sciences (NASDAQ:EXAS - Get Free Report) last announced its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.23. The business had revenue of $713.42 million during the quarter, compared to analyst estimates of $701.45 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. On average, equities analysts expect that Exact Sciences Co. will post -0.58 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research analysts have weighed in on the stock. BTIG Research lifted their price target on shares of Exact Sciences from $65.00 to $75.00 and gave the company a "buy" rating in a research note on Tuesday, November 26th. Piper Sandler dropped their price objective on Exact Sciences from $75.00 to $70.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. TD Cowen upped their target price on shares of Exact Sciences from $82.00 to $86.00 and gave the company a "buy" rating in a report on Tuesday, November 26th. Bank of America decreased their price objective on shares of Exact Sciences from $72.00 to $65.00 and set a "buy" rating on the stock in a report on Thursday, February 20th. Finally, William Blair reiterated an "outperform" rating on shares of Exact Sciences in a research note on Thursday, February 20th. Two analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Exact Sciences currently has an average rating of "Moderate Buy" and a consensus target price of $70.83.
Check Out Our Latest Analysis on EXAS
About Exact Sciences
(
Free Report)
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Read More
Before you consider Exact Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exact Sciences wasn't on the list.
While Exact Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
